Eyenovia (NASDAQ:EYEN) Receives “Buy” Rating from HC Wainwright

Eyenovia (NASDAQ:EYEN)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $12.00 price target on the stock.

Separately, William Blair raised shares of Eyenovia to a “strong-buy” rating in a research report on Friday, August 30th.

Eyenovia Stock Performance

Shares of EYEN opened at $0.51 on Wednesday. The company has a debt-to-equity ratio of 3.72, a quick ratio of 0.27 and a current ratio of 0.46. The company has a market capitalization of $32.37 million, a PE ratio of -0.63 and a beta of 1.75. Eyenovia has a 52 week low of $0.37 and a 52 week high of $2.57. The company’s 50 day moving average price is $0.51 and its 200 day moving average price is $0.72.

Eyenovia (NASDAQ:EYEN) last posted its earnings results on Monday, August 12th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $1.38 million. Eyenovia had a negative return on equity of 547.46% and a negative net margin of 116,506.25%. Research analysts expect that Eyenovia will post -0.56 EPS for the current fiscal year.

Insider Buying and Selling at Eyenovia

In other Eyenovia news, CEO Michael M. Rowe purchased 50,000 shares of the stock in a transaction dated Monday, August 26th. The stock was bought at an average price of $0.57 per share, for a total transaction of $28,500.00. Following the transaction, the chief executive officer now directly owns 82,927 shares in the company, valued at $47,268.39. This represents a 100.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 7.10% of the company’s stock.

Institutional Investors Weigh In On Eyenovia

Several institutional investors have recently modified their holdings of EYEN. BNP Paribas Financial Markets grew its position in shares of Eyenovia by 1,444.4% during the 1st quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after buying an additional 205,390 shares during the period. Vanguard Group Inc. boosted its stake in Eyenovia by 25.2% during the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after acquiring an additional 360,924 shares during the last quarter. Nations Financial Group Inc. IA ADV boosted its stake in Eyenovia by 24.4% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after acquiring an additional 10,000 shares during the last quarter. Ground Swell Capital LLC bought a new position in Eyenovia during the 2nd quarter worth approximately $27,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Eyenovia during the 2nd quarter worth approximately $26,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.